Avalyn Pharma (AVLN) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | DMRA |
|---|---|---|
| Share price | $25.72 | $20.56 |
| Market cap | $1.14B | $1.27B |
| 1-day change | +0.74% | +1.58% |
| YTD return | — | -10.65% |
| 1-year return | — | +93.05% |
| 5-year return | — | -75.95% |
| EPS (TTM) | $-2.47 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $38.33 |
| 52-week low | $24.14 | $4.95 |
| Distance from 52-week high | -35.97% | -46.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +140.28% | +128.06% |
| Average volume | 245.04K | 531.94K |
| Shares outstanding | 44.33M | 61.74M |
| Employees | 55 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
AVLN vs DMRA FAQ
Which is bigger, Avalyn Pharma or Damora Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.14B for Avalyn Pharma (AVLN).
Are Avalyn Pharma and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.